New drink draws criticism

Feb 12, 2007

Connecticut's attorney general has opened an investigation into the calorie-burning claims of a caffeinated drink from the Coca-Cola and Nestle companies.

Called Enviga, the 5-calorie drink has been shown to help people who are already thin increase their energy expenditure according to a study published Monday in the journal of Obesity, USA Today reported.

In the study funded by Nestle, Swiss researchers had 31 lean, young adults drink three cans of Enviga for three days.

On the third day, participants burned on average 106 extra calories or the equivalent of two regular Oreo cookies.

Last week the non-profit Center for Science in the Public Interest filed suit against the manufacturers, accusing them of fraudulent marketing and labeling.

The director of nutrition and health policy for Coca-Cola says Enviga is not being positioned as a weight-loss product.

Copyright 2007 by United Press International

Explore further: 'Beach body' ads investigated after outcry in Britain

Related Stories

FAA's Airworthiness Directive issued to avoid power loss

19 hours ago

A fix for a software problem that could possibly result in power loss in Boeing 787s has been ordered. Federal Aviation Administration officials adopted a new airworthiness directive (AD), effective as of ...

More than 2,200 confirmed dead in Nepal earthquake

Apr 26, 2015

A powerful aftershock shook Nepal on Sunday, making buildings sway and sending panicked Kathmandu residents running into the streets a day after a massive earthquake left more than 2,200 people dead.

Recommended for you

Dutch DSM posts Q1 slump

Apr 29, 2015

Dutch pharmaceutical group DSM posted a 70 million euro first quarter net loss Wednesday despite an 11 percent jump in sales, boosted by higher animal nutrition volumes and favourable exchange rates.

New meds help drugmakers weather strong dollar, other issues

Apr 28, 2015

Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer Inc., Merck & Co. and Bristol-Myers Squibb ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.